All In Biotech

Drug Trial Radar · NCT06550830

Clinical Trial of PCV24 in Children Aged 2-17 Years

A Randomized, Double-blind, Controlled Combined With Open-label Phase Ia Clinical Trial to Evaluate the Safety and Immunogenicity of 24-valent Pneumococcal Conjugate Vaccine in Children Aged 2-17 Years.

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 119 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

119

Actual

Start

Sep 7, 2024

Primary completion

Jun 25, 2025

Study completion Jun 25, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase Ia clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2-17 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, controlled combined with open-label phase Ia clinical trial.

Conditions

  • Pneumococcal Infectious Disease

Interventions

  • Sinovac PCV24 formulation 1Biological

    One dose of Sinovac PCV24 formulation 1(0.5mL)

  • Sinovac PCV24 formulation 2Biological

    One dose of Sinovac PCV24 formulation 2(0.5mL)

  • Prevenar13®Biological

    One dose of PCV13 manufactured by Pfizer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse reactionsTime frame: 0-30 days after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.